ArticleAntimicrobial resistance and infection control2021
Bloodstream infections caused by ST2 Acinetobacter baumannii: risk factors, antibiotic regimens, and virulence over 6 years period in China.
Article in Antimicrobial resistance and infection control, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 2 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- Tracking of multidrug-resistant pathogen clones in Ghana: a systematic review and meta-analysis.BMC medical genomics · 2025Pooled it
- Geographical mapping and temporal trends of Acinetobacter baumannii carbapenem resistance: A comprehensive meta-analysis.PloS one · 2024Pooled it
- The population structure ofApplied and environmental microbiology · 2026Article
- Integrated clinical and genomic characterization ofJournal of medical microbiology · 2026Article
- Multidrug-resistant Acinetobacter spp. bloodstream infections in hematologic patients: clinical characteristics, genomic features, and eravacycline-based combination therapy.BMC infectious diseases · 2026Article
- Genomic insights into the genetic diversity, resistance determinants, and plasmid content of carbapenem-resistant Acinetobacter baumannii clinical isolates.Archives of microbiology · 2026Article
- Genomic characterisation of extensively drug-resistant Acinetobacter baumannii isolates from a tertiary hospital in Ghana.PloS one · 2026Article
- Comparative genomic insights into carbapenem-resistant versus susceptibleFrontiers in cellular and infection microbiology · 2026Article
- Clonal Diversity and Resistome Dynamics ofMedicina (Kaunas, Lithuania) · 2025Article
- Prognostic Indicators of Carbapenem-ResistantHealth science reports · 2025Review
- Development and clinical application of a PCR-UV assay for detection of carbapenem resistant Acinetobacter baumannii in bloodstream infections.Microbial cell factories · 2025Article
- The evolution of the multidrug-resistant and globally distributed ST2 Acinetobacter baumannii in China.BMC microbiology · 2025Article
- Genetic Characteristics ofPathogens (Basel, Switzerland) · 2025Article
- Gallium nitrate inhibits multidrug-resistant Acinetobacter baumannii isolated from bloodstream infection by disrupting multiple iron-dependent metabolic processes.BMC microbiology · 2025Article
- Genomic epidemiology and phylodynamics of Acinetobacter baumannii bloodstream isolates in China.Nature communications · 2025Article
- Expression of bap gene in multidrug-resistant and biofilm-producing Acinetobacter baumannii clinical isolates.BMC microbiology · 2025Article
- Risk and Prognostic Factors for Bloodstream Infections Due to Clonally TransmittedInfection and drug resistance · 2025Article
- Exploring the clinical outcomes and molecular characteristics ofFrontiers in cellular and infection microbiology · 2025Article
- Molecular characterization of carbapenem-resistant and carbapenem-sensitiveFrontiers in microbiology · 2025Article
- Genomic Insights of Multidrug-Resistant Enterococcus faecalis and Acinetobacter baumannii Isolated from a Sepsis Patient with Pauci-Immune Crescentic Glomerulonephritis, India.Current microbiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBloodstream infection (BSI) caused by multidrug-resistant Acinetobacter baumannii (MDR-AB) has been increasingly observed among hospitalized patients. The following study analyzed the epidemiology and microbiological characteristics of MDR-AB, as well as the clinical features, antimicrobial treatments, and outcomes in patients over a six years period in China.
methodsThis retrospective study was conducted in a large tertiary hospital in China between January 2013 and December 2018. The clinical and microbiological data of all consecutive hospitalized patients with MDR-AB induced bloodstream infection were included and analyzed.
resultsA total of 108 BSI episodes were analyzed. All MDR isolates belonged to ST2, a sequence type that has spread all over the world. Overall, ST2 strains showed strong biofilm formation ability, high serum resistance, and high pathogenicity. As for the clinical characteristics of the patient, 30-day mortality was 69.4% (75/108). The three main risk factors included mechanical ventilation, intensive care unit (ICU) stay, and thrombocytopenia; three protective factors included a change of antimicrobial regimen within 48 h after positive blood culture, use of the antibacterial agent combination, and more inpatient days. The most effective antibacterial regimen was the combination of cefoperazone/sulbactam and tigecycline.
conclusionsBSI caused by ST2 A.baumannii represents a difficult challenge for physicians, considering the high mortality associated with this infection. The combination of cefoperazone/sulbactam and tigecycline may be an effective treatment option.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.